Mark Treherne

Non-Executive Director

Mark has served as Director since 2008. Mark has over 30 years’ experience in drug discovery and development and has raised over €200M and out-licenced numerous therapeutic assets. He served on the boards of 15 private and public companies. Mark is currently Chairman of Talisman Therapeutics, Ubiquigent and NuVision Biotherapies. Previously Mark worked with Senexis and has co-founded Cambridge Drug Discovery as Chief Executive in 1997 and sold it in 2001 to BioFocus, which was subsequently acquired by Galapagos and then sold on to Charles River. Mark also worked at Pfizer to lead the European neurodegeneration team. Mark started his career as a Biozentrum Fellow at the University of Basel. He holds a B.Sc. in Physiology and Pharmacology from St Andrews University in Scotland (1983) and a Ph.D. in receptor pharmacology from the University of Cambridge, UK (1987).